Search

Your search keyword '"Liew, Danny"' showing total 862 results
Start Over Author "Liew, Danny" Search Limiters Full Text
862 results on '"Liew, Danny"'

4. Delayed return of bowel function after general surgery in South Australia

Author

Kovoor, Joshua G., Bacchi, Stephen, Stretton, Brandon, Gupta, Aashray K., Jacobsen, Jonathan Henry W., To, Minh-Son, Goh, Rudy, Hewitt, Joseph N., Ovenden, Christopher D., Warren, Leigh, Marshall-Webb, Matthew, Jones, Karen L., Reddi, Benjamin A., Liew, Danny, Dobbins, Christopher, Padbury, Robert T., Hewett, Peter J., Hugh, Thomas J., Trochsler, Markus I., and Maddern, Guy J.

Published
2024
Full Text
View/download PDF

5. A Nonrandomized Pilot Study to Investigate the Acceptability and Feasibility of LivR Well: A Multifaceted 28-Day Home-Based Liver Optimization Program for Acute-on-Chronic Liver Failure

Author

Ngu, Natalie L.Y., Saxby, Edward, Worland, Thomas, Anderson, Patricia, Stothers, Lisa, Hunter, Jo, Elford, Alexander T., Ha, Phil, Hartley, Imogen, Roberts, Andrew, Seah, Dean, Tambakis, George, Connoley, Declan, Figredo, Anita, Ratnam, Dilip, Liew, Danny, Rogers, Benjamin, Sievert, William, Bell, Sally, and Le, Suong

Published
2024
Full Text
View/download PDF

7. Effects of Statins for Secondary Prevention on Functioning and Other Outcomes Among Nursing Home Residents

Author

Zullo, Andrew R, Ofori-Asenso, Richard, Wood, Marci, Zuern, Allison, Lee, Yoojin, Wu, Wen-Chih, Rudolph, James L, Liew, Danny, and Steinman, Michael A

Subjects
Health Services and Systems, Health Sciences, Aging, Cardiovascular, Clinical Research, Prevention, Health Services, Rehabilitation, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Aged, Aged, 80 and over, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Medicare, Nursing Homes, Retrospective Studies, Secondary Prevention, United States, Hydroxymethylglutaryl-CoA reductase, inhibitors, frailty, nursing homes, secondary prevention, activities of daily living, Hydroxymethylglutaryl-CoA reductase inhibitors, Clinical Sciences, Nursing, Public Health and Health Services, Geriatrics, Health services and systems, Public health
Abstract

ObjectivesStudies examining the effects of statins after acute myocardial infarction (AMI) excluded frail older adults, especially nursing home (NH) residents, and few examined functional outcomes. Older NH residents may benefit less from statins and be particularly susceptible to adverse drug events like myopathy-related functional decline. We evaluated the effects of statins on 1-year functional decline, rehospitalization, and death in NH residents.DesignWe conducted a retrospective cohort study using 2007-2010 linked national data from Minimum Data Set (MDS) assessments, Medicare claims, and Online Survey Certification and Reporting System records.Setting and participantsWe included US NH residents 65 years and older who were statin nonusers, were hospitalized for AMI between May 2007 and March 2010, and returned to the NH.MeasuresOutcomes were functional decline, death, and rehospitalization in the first year after post-AMI NH admission. New statin users were 1:1 propensity-score matched to nonusers to adjust for 92 characteristics. We estimated hazard ratios (HRs) and restricted mean survival time differences with 95% confidence intervals (CIs) comparing individuals who did vs did not initiate statin therapy after AMI hospitalization.ResultsPropensity-score matching yielded a cohort of 5440 residents. Mean age was 83 years and 69% were female. Statin use was associated with a reduction in mortality (HR 0.80, 95% CI 0.73-0.87), corresponding to a mean of 15.9 (95% CI 9.9-22.0) days of extended life expectancy. No overall differences in rehospitalization (HR 1.06, 95% CI 0.98-1.14) or functional decline (HR 1.00, 95% CI 0.88-1.14) were observed.Conclusions and implicationsStatins may reduce 1-year mortality by 20% without affecting function among older NH residents who wish to live longer after AMI. During shared decision making with these patients or their representatives, clinicians should consider communicating that the average benefit of statins is 16 days of additional survival over 1 year.

Published
2020

14. A home-based, multidisciplinary liver optimisation programme for the first 28 days after an admission for acute-on-chronic liver failure (LivR well): a study protocol for a randomised controlled trial

Author

Ngu, Natalie LY, Saxby, Edward, Worland, Thomas, Anderson, Patricia, Stothers, Lisa, Figredo, Anita, Hunter, Jo, Elford, Alexander, Ha, Phil, Hartley, Imogen, Roberts, Andrew, Seah, Dean, Tambakis, George, Liew, Danny, Rogers, Benjamin, Sievert, William, Bell, Sally, and Le, Suong

Published
2022
Full Text
View/download PDF

37. Number needed to treat and cost per responder of Janus kinase inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis in Japan

Author

1000020301905, Atsumi, Tatsuya, Asakura, Eri, Doi, Michio, Sawant, Ruta, Kawaguchi, Isao, Sasaki, Nobuhito, Liew, Danny, 1000020301905, Atsumi, Tatsuya, Asakura, Eri, Doi, Michio, Sawant, Ruta, Kawaguchi, Isao, Sasaki, Nobuhito, and Liew, Danny

Abstract

Objective This study evaluated the effectiveness and cost-effectiveness of baricitinib, tofacitinib, and upadacitinib regimens, compared to conventional synthetic disease-modifying antirheumatic drug (csDMARD) alone, among Japanese patients with moderate-to-severe rheumatoid arthritis (RA) inadequately responsive to csDMARD, measured in terms of number needed to treat (NNT) and cost per responder (CPR). Methods Efficacy data were derived from two recent network meta-analyses among global and Japanese population. The cost perspective was that of the Japanese Health Service. Both NNT and CPR were based on disease activity score for 28 joints with C-reactive protein (DAS28-CRP) remission and American College of Rheumatology (ACR) 20/50/70 at 12 and 24 weeks. Results Over 12 weeks, the median NNT and the median CPR to achieve DAS28-CRP remission were 4.3 and JPY 1,799,696 [USD 16,361], respectively, for upadacitinib 15 mg + csDMARD. The equivalent results were 6.0 and JPY 2,691,684 [USD 24,470] for baricitinib 4 mg + csDMARD and 5.6 and JPY 2,507,152 [USD 22,792] for tofacitinib 5 mg + csDMARD. Similar rankings were observed at 24 weeks and for other outcomes. Conclusions Upadacitinib 15 mg was associated with the lowest NNT and CPR among the three Janus kinase inhibitors used in treatment regimens for Japanese patients with moderate-to-severe RA inadequately responsive to csDMARD.

Published
2023

38. Number needed to treat and cost per responder of Janus kinase inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis in Japan

Author

Atsumi, Tatsuya, Asakura, Eri, Doi, Michio, Sawant, Ruta, Kawaguchi, Isao, Sasaki, Nobuhito, Liew, Danny, Atsumi, Tatsuya, Asakura, Eri, Doi, Michio, Sawant, Ruta, Kawaguchi, Isao, Sasaki, Nobuhito, and Liew, Danny

Abstract

Objective This study evaluated the effectiveness and cost-effectiveness of baricitinib, tofacitinib, and upadacitinib regimens, compared to conventional synthetic disease-modifying antirheumatic drug (csDMARD) alone, among Japanese patients with moderate-to-severe rheumatoid arthritis (RA) inadequately responsive to csDMARD, measured in terms of number needed to treat (NNT) and cost per responder (CPR). Methods Efficacy data were derived from two recent network meta-analyses among global and Japanese population. The cost perspective was that of the Japanese Health Service. Both NNT and CPR were based on disease activity score for 28 joints with C-reactive protein (DAS28-CRP) remission and American College of Rheumatology (ACR) 20/50/70 at 12 and 24 weeks. Results Over 12 weeks, the median NNT and the median CPR to achieve DAS28-CRP remission were 4.3 and JPY 1,799,696 [USD 16,361], respectively, for upadacitinib 15 mg + csDMARD. The equivalent results were 6.0 and JPY 2,691,684 [USD 24,470] for baricitinib 4 mg + csDMARD and 5.6 and JPY 2,507,152 [USD 22,792] for tofacitinib 5 mg + csDMARD. Similar rankings were observed at 24 weeks and for other outcomes. Conclusions Upadacitinib 15 mg was associated with the lowest NNT and CPR among the three Janus kinase inhibitors used in treatment regimens for Japanese patients with moderate-to-severe RA inadequately responsive to csDMARD.

Published
2023

47. Incidence, predictors and clinical implications of new renal impairment following percutaneous coronary intervention

Author

Wong, Nathan, primary, Dinh, Diem T, additional, Brennan, Angela, additional, Batchelor, Riley, additional, Duffy, Stephen J, additional, Shaw, James A, additional, Chan, William, additional, Layland, Jamie, additional, van Gaal, William J, additional, Reid, Christopher M, additional, Liew, Danny, additional, and Stub, Dion, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results